Compare Incyte Corporation (INCY) vs iShares Russell 2000 ETF (IWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs iShares Russell 2000 ETF — how do they compare? Incyte Corporation trades at $113.34 (market cap $22.85B), while iShares Russell 2000 ETF trades at $279.42 (market cap $77.70B). The key difference: iShares Russell 2000 ETF is far larger — about 3.4× Incyte Corporation's market cap, and iShares Russell 2000 ETF is more actively traded (35,598,983 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and iShares Russell 2000 ETF for 83 Days on average.
| INCY | IWM | |
|---|---|---|
Market Cap | $22.85B | $77.70B |
Volume | 1,927,029 | 35,598,983 |
Sector | Health | — |
52-Week High | $129.93 | $305.06 |
52-Week Low | $83.80 | $229.13 |
Typical Hold Time | 33 Days | 83 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
IWM, the iShares Russell 2000 ETF tracking US small-cap stocks, trades at $279.1, up 0.5% on the day. Technical indicators are predominantly bearish, with moving averages and ADX signaling a downtrend, though oscillators like RSI are neutral. The fund lacks traditional valuation ratios as it is an ETF, and recent news highlights its underperformance versus the S&P 500 over the past decade, with concerns about its inclusion of unprofitable companies.
The outlook for IWM is clouded by persistent underperformance and sensitivity to interest rate hikes, which pressure small caps. While offering diversification away from large-cap tech, the fund faces headwinds from economic tightening and narrow market breadth. A rebound hinges on broader market participation and favorable macroeconomic conditions, but near-term risks remain elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →
